(B) Overall survival is shown. lines and patient-derived xenografts to show the effect of these BsAbs in vivo. == Results == In vitro, the IgV-targeting BsAb experienced higher binding to AML cell lines using circulation cytometry and delivered more potent cytotoxicity in T-cell-dependent cytotoxicity assays; importantly, the IgC domain-targeting outperformed the IgV domain-targeting BsAb in medullary and extramedullary leukemia animal models. == Conclusions == These data support further clinical development of this BsAb for first-in-human phase I clinical trial. Keywords:immunotherapy, antibodies, neoplasm, antigens, neoplasm == Introduction == Leukemia is the most common malignancy in children. Despite Pirozadil improvements in the treatment of acute lymphoblastic leukemia, patients with acute myeloid leukemia (AML) Pirozadil have a much worse prognosis, with a 3-12 months overall survival rate of about 20%.1The outcome of adult patients with AML is even poorer, with only 6% of patients older than 65 surviving 2 years after diagnosis.2There is an obvious unmet need for better AML therapies. CD33, a member of the sialic acidbinding immunoglobulin-like (Ig-like) lectin family, is expressed on most AML. The CD33 extracellular domain name is composed of a membrane distal immunoglobulin V (IgV) and a membrane proximal immunoglobulin C (IgC) domain name. Current anti-CD33 antibodies in clinical trials, including the only Food and Drug Administration-approved antibody gemtuzumab ozogamicin (GO), target the IgV domain name. Single nucleotide polymorphism (SNP) rs12459419 C>T in exon 2 of CD33 antigen eliminates the expression of the IgV domain name and reduces the expression of the full-length protein. This SNP, which occurs in almost 50% of AML cases, renders the patients unresponsive to GO, a drug that targets the IgV domain name.3To tackle this splice variant heterogeneity, we generated T cell engaging bispecific antibodies (BsAbs) targeting the IgV and IgC domains and compare their function in vitro and potency in vitro in xenograft models of human AML. == Materials and methods == == Antibody humanization == The murine M195 anti-CD33 antibody was humanized as explained earlier.4The murine My96 anti-CD33 was humanized by grafting the heavy chain complementarity determining region (CDR) sequences onto the human framework IGHV1-46*01 and IGHJ4*01 and the light chain CDR sequences onto the human framework IGKV4-1*01 and IGKJ4*01. The murine HIM3-4 anti-CD33 was humanized Pirozadil by grafting the heavy chain CDR sequences onto the human framework IGHV1-2*02 and IGHJ4*01 and the light chain CDR sequences onto the human framework IGKV1-33*01 and IGKJ2*01. The CD3xCD33 BsAbs were designed using heavy chain variable region fragment/light chain variable region fragment (VH/VL) domains from huM195, huMy96, and huHIM3-4 antibodies and huOKT3 scFv fused to the C terminus of the light chain of a human IgG1 Pirozadil as previously explained and were named BC133, BC269, and BC275, respectively.5The N297A and K322A mutations were generated to eliminate Fc glycosylation and complement binding, respectively.6 == Surface plasmon resonance == Human CD33 (Sino Biological, Cat # 12238-H08H) was immobilized BRIP1 on a CM5 chip. Serial twofold dilutions of the BsAbs (starting at 100 nM) were flowed over the chip using a Biacore T200 system. Binding kinetics were measured at 37C. The sensorgrams were fitted with a two-state binding model. == Cytotoxicity assay (51Cr release assay) == Leukemia cells were cultured in RPMI 1640 medium (Cellgro) supplemented with 10% heat-inactivated Pirozadil fetal bovine serum (FBS) (Life Technologies) at 37C in a 5% CO2humidified incubator. Standard chromium release cytotoxicity assays were performed using activated human T cells as explained before.4 == T cell activation, proliferation, and cytokine release == Buffy coats were purchased from the New York Blood Center. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using the lymphocyte separation medium (Corning, Cat # 25-072-CV). T cells were purified from PBMCs using the EasySep Human T Cell Isolation Kit (Stem Cell Technologies, Cat # 17951). For T cell proliferation assays, carboxyfluorescein succinimidyl ester (CFSE)-labeled (Thermo Scientific, Cat #C34554) effector cells were mixed with AML.